Table 2.
Univariable and multivariable analysis of factors associated with overall survival in low-risk patients.
| Characteristic | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
| Age at surgery* | 1.89 (1.62, 2.21) | <0.001 | 1.80 (1.52, 2.12) | <0.001 |
| BMI* | 1.06 (0.98, 1.15) | 0.16 | ||
| Pulmonary disease† | <0.001 | 0.003 | ||
| No | Reference | Reference | ||
| Yes | 2.13 (1.48, 3.05) | 1.78 (1.21, 2.61) | ||
| Cardiovascular disease‡ | <0.001 | 0.001 | ||
| No | Reference | Reference | ||
| Yes | 3.65 (2.45, 5.42) | 2.04 (1.32, 3.15) | ||
| Diabetes | 0.026 | |||
| No | Reference | |||
| Yes | 1.51 (1.05, 2.16) | |||
| Smoking history | 0.11 | |||
| No | Reference | |||
| Yes | 1.31 (0.94, 1.81) | |||
| ASA score | <0.001 | |||
| ≤2 | Reference | |||
| >2 | 2.32 (1.68, 3.20) | |||
| 2009 FIGO stage | <0.001 | <0.001 | ||
| Ia | Reference | Reference | ||
| Ib or II | 2.34 (1.51, 3.64) | 1.70 (1.05, 2.75) | ||
| IIIa, IIIb, IIIc1, or IIIc2 | 7.38 (4.72, 11.51) | 4.80 (2.31, 9.99) | ||
| IV | 12.46 (7.03, 22.09) | 16.33 (8.24, 32.35) | ||
| LVSI | 0.022 | |||
| No | Referent | |||
| Yes | 1.72 (1.08, 2.73) | |||
| Residual disease | <0.001 | |||
| No | Reference | |||
| Yes | 21.94 (7.92, 60.75) | |||
| Primary tumor diameter | <0.001 | 0.001 | ||
| ≤2 cm | Reference | Reference | ||
| >2 cm | 3.07 (2.02, 4.66) | 2.22 (1.38, 3.58) | ||
| Cervical stromal invasion | <0.001 | |||
| No | Reference | |||
| Yes | 5.06 (2.96, 8.66) | |||
| Myometrial invasion* | 1.23 (1.17, 1.29) | <0.001 | ||
| Gross extrauterine disease | <0.001 | |||
| No | Reference | |||
| Yes | 9.61 (5.30, 17.45) | |||
| Adnexal involvement | <0.001 | |||
| No | Reference | |||
| Yes | 9.23 (5.29, 16.11) | |||
| Serosal involvement | <0.001 | |||
| No | Reference | |||
| Yes | 9.07 (4.89, 16.86) | |||
| Peritoneal cytology | <0.001 | |||
| Negative | Reference | |||
| Positive | 2.77 (1.72, 4.46) | |||
| Laparotomy | 0.37 | |||
| No | Reference | |||
| Yes | 0.82 (0.54, 1.26) | |||
| Pelvic lymph node status | <0.001 | 0.001 | ||
| No or inadequate/negative LND | 1.10 (0.77, 1.56) | 2.01 (1.36, 2.98) | ||
| Adequate/negative LND | Reference | Reference | ||
| Positive pelvic nodes | 6.41 (4.01, 10.27) | 1.15 (0.54–2.49) | ||
| Paraaortic lymph node status | <0.001 | |||
| No or inadequate/negative LND | 0.80 (0.55, 1.16) | |||
| Adequate/negative LND | Reference | |||
| Positive para-aortic nodes | 4.50 (2.37, 8.54) | |||
| Adjuvant therapy | <0.001 | |||
| No adjuvant therapy | Reference | |||
| Vaginal BT or EBRT ± BT | 1.94 (1.33, 2.84) | |||
| Chemo ± BT or chemo and EBRT ± BT | 2.52 (1.26, 503) | |||
| 30-day postoperative complications | <0.001 | <0.001 | ||
| None or grade 1 | Reference | Reference | ||
| Grade 2 or 3 | 2.83 (2.01, 3.99) | 2.03 (1.42, 2.91) | ||
| Grade 4, 5, or 6 | 3.17 (1.46, 6.91) | 3.97 (1.76, 8.98) | ||
Abbreviations: LND, lymphadenectomy; FIGO, International Federation of Gynecology and Obstetrics; ASA, American Society of Anesthesiologists, PA, para-aortic; EBRT, external beam radiotherapy; BT, brachytherapy.
Hazard ratio per 10-year increase in age, 5-kg/m2 increase in body mass index (BMI), and 10-unit increase in percent of myometrial invasion.
Pulmonary disease is defined as a report of at least one of the following: dyspnea, history of severe chronic obstruction pulmonary disease (COPD), current pneumonia, history of sleep apnea, or past/current CPAP use.
Cardiovascular disease is defined as a report of at least one of the following: congestive heart failure (CHF) within 30 days, history of myocardial infarction (MI) within 6 months, previous cardiac stenting, previous cardiac surgery, history of angina within 30 days, history of revascularization/amputation for peripheral vascular disease (PVD), or rest pain/gangrene.